Chemotherapies drugs and monoclonal antibodies are key components of the treatment of cancer patients
and patients with chronic inflammatory conditions to provide increase in life expectancy and quality of life.
Their increased use has lead to an increase in drugs hypersensitivity reactions (DHR) worldwide. DHR to those
agents prevented their use and promoted the use of second line therapies to protect patients’ hypersensitive reactions
and anaphylaxis. Second line medications may not fully address the patients’ medical condition and it is
desirable to keep patients on first line therapy.
Drug hypersensitivity symptoms can range from mild cutaneous reactions to life-threatening anaphylaxis.
Rapid drug desensitization (RDD) is a novel approach to the management of drug hypersensitivity reactions which
are IgE and non-IgE mediated. Through the diferent desensitization protocols patients can receive the full dose
of the medications that they have presented a hypersensitive reaction and been protected against anaphylaxis.
This review looks at the current literature on hypersensitivity reactions (HSR) to chemotherapy drugs and monoclonal
antibodies and the potential use of RDD for their management.